This Plain Language Summary of Publication article (PLSP) from Future Oncology compared nivolumab plus chemotherapy versus placebo plus chemotherapy in 521 patients with newly diagnosed, high-risk estrogen-positive breast cancer. Researchers measured complete cancer clearance rates, assessed treatment side effects, and used biomarkers to identify which patients were most likely to benefit from nivolumab treatment.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial’ and was published in Nature Medicine.

Visit Nature using the link to read the original article.